Redhill Biopharma (RDHL)
(Real Time Quote from BATS)
$0.46 USD
0.00 (0.63%)
Updated May 15, 2024 02:50 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RDHL 0.46 0.00(0.63%)
Will RDHL be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for RDHL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RDHL
RedHill Biopharma (RDHL) Up on New Patent for COVID-19 Candidate
RedHill (RDHL) Up on Orphan Drug Tag for NTM Disease Drug
RDHL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Redhill Biopharma Ltd. (RDHL) Could Find Support Soon, Here's Why You Should Buy the Stock Now
Other News for RDHL
Odysight.ai Announces Appointment of Einav Brenner as Chief Financial Officer
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
RedHill Biopharma Secures Opaganib Patent in China
RedHill Biopharma issued Chinese patent Notice of Allowance covering opaganib
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study